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[57] ABSTRACT 
Compounds including phloretin and/ or phlorizin deriv 
atives coupled to an undigestible and non-absorbable 
matrix are provided. The compounds have pharmaco 
logical ef?cacies. They inhibit sugar uptake from the 
intestine and may be used in composition form in meth 
ods for treating diabetes and for promoting weight loss. 
A method for the manufacture of these compounds and 
a novel intermediate phlorizin derivative for making 
these compounds are also disclosed. 
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PHLORETIN AND PHLORIZIN DERIVATIVE 
CONTAINING COMPOUNDS 
TECHNICAL FIELD 
The present invention relates to innovative com 
pounds having phloretin or phlorizin moieties and their 
use as a new and novel class of clinically safe pharmaco 
logical agents. More particularly, the present invention 
relates to certain new phloretin and phlorizin derivative 
containing compounds, pharmaceutical compositions 
thereof, their methods of preparation, and their meth 
ods of use in inhibiting sugar uptake from the small 
intestine for the treatment of diabetes, obesity and 
dumping syndrome. 
BACKGROUND ART 
Current pharmacological therapy for the overweight 
patient focuses on two approaches: appetite regulation 
and modulation of intestinal absorption processes. The 
?rst approach involves the administration of anoretic 
agents, such as amphetamines, to the patient in order to 
control caloric intake. Typically, the amphetamines are 
used as short term adjuncts to a nutritionally and/or 
behaviorally designed weight reduction program. 
While these agents are strong suppressors of appetite, 
their systemic action is associated with dangerous cen 
tral nervous system side effects and humeral/neuro 
transmitter imbalances. 
The second approach to control body weight in 
volves the reduction of the availability of nutrients by 
affecting digestion and/or absorption. The success of 
intestinal by-pass operations for the treatment of obesity 
has encouraged the search for oral agents which might 
produce a chemically induced, reversible form of al 
tered intestinal absorption. A number of compounds 
have been examined in studies designed to block the 
intestinal uptake of lipids. Such an approach, however, 
disadvantageously causes essential lipid-soluble vitamin 
malabsorption and other serious disorders (Dobbins, W. 
0., Herrero, B. A. and Mansbach, C. M., Am. J. Med. 
Sci. 255 (1968) 63; Bray, G. A., “Drug Therapy for the 
Obese Patient” in The Obese Patient, (1976) p. 353, Saun 
ders, Philadelphia; and Evans, E., Miller, D. 8., Samuel, 
P. D. and Burland, W. L., Postgrad. Med. J. 51, Suppl. 
1 (1975) 1204). 
In order to avoid this problem, recent research has 
been directed toward the development of “starch block 
ers”. An example of these is a preparation of amylase 
inhibitors which are proposed to block carbohydrate 
absorption (Keup, V. and Puls, W., Arch. Pharmacol. 
297 Suppl. (1975) R85). The rationale for this approach 
relies on the fact that the enzyme amylase, normally 
secreted in saliva and from the pancreas, hydrolyzes 
starch randomly to glucose and maltose. The maltose is 
then degraded by maltase to the mono-saccharide glu 
cose. The monosaccharides are the only form of any 
dietary carbohydrate that is absorbed by intestinal 
transport mechanisms. Thus, if the amylase is inhibited 
from hydrolyzing the starch, intestinal absorption is 
blocked. Over 100 different varieties of these “starch 
blocker” preparations have been placed on the market. 
They are widely sold by pharmacies and health food 
stores. The use of these “over-the-counter” offerings 
has been so attractive that over a million tablets were 
consumed daily in the United States during the first part 
of 1982. These consumption ?gures indicate that the 
public is remarkably responsive to claims for diet and 
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food supplements promising a short cut to weight con 
trol without dietary discipline. Despite the commercial 
success of these starch blockers, however, there is no 
evidence that these preparations actually inhibit starch 
or calorie absorption in vivo. In fact, in a decisive study 
with human volunteers, Fordran and his coworkers 
showed no increase in calories lost in feces caused by 
these amylase inhibitors (Bo-Linn, G. W., Santa Ava, C. 
A., Morawski, S. G. and Fordran, J. S., New Engl. J. 
Med. 307 (1982) 1413). 
It is generally accepted that the transport system 
responsible for the active renal reabsorption of D 
glucose is localized in the luminal membrane or brush 
border of proximal tubular cells (see Vick, Diedrich and 
Baumann, Am. J. of PhysioL, Vol. 224, No. 3, March 
(1973) 552-557). Experimental evidence indicates that 
the glucose interacts with a component or carrier of the 
membrane that facilitates the entry of the sugar into the 
cells. For example, the ?nal step in carbohydrate as 
similiation by the small intestine has been shown to be 
the active absorption of enzyme generated mono-sac 
charides via a Na+-dependent transporter in the epithe 
lial brush border membranes. 
Phlorizin is known to be a highly effective and spe 
ci?c blocker of sugar absorption from the intestinal 
tract. In fact, studies have indicated that this naturally 
occurring compound found in the bark and other com 
ponents of apple and other fruit trees is a potent compet 
itive inhibitor of the sugar transport process having an 
af?nity for the sugar transporter of about 1,000 times 
greater than D-glucose (Bode, F., Baumann, K., and 
Diedrich, D. F., Biochem. Biophys. Acta 290 (1972) 
134). Phlorizin, however, is not a clinically useful and 
safe pharmacological agent that may be used in the 
management of diabetic and obese patients. 
Orally administered phlorizin not only blocks the in 
vivo intestinal absorption of glucose in rats and dogs but 
it also causes a “phlorizin diabetes” or glucosuria. Some 
of the phlorizin survives the hydrolytic environment of 
the gastrointestinal tract, is absorbed intact, and is car 
ried to the kidneys where it blocks the sugar trans 
porter. Furthermore, as some of the phlorizin travels 
through the digestive system, it is hydrolyzed by the 
intestinal epithelia to phloretin (Diedrich, D. F., Arch. 
Biochem. Biophys, 127 (1968) 803) which readily enters 
the blood stream to cause at appropriate levels pro 
found toxic effects at all sites in the body. 
While phlorizin is not a clinically useful and safe 
pharmacological agent, it is a valuable study tool. Tests 
and studies of phlorizin have shown that the- glucose 
moiety of phlorizin is an essential substituent of a potent 
sugar uptake inhibitor molecule. Experimental results 
bear out this postulate with regard to at least a part of 
this moiety (Diedrich, D. F., “In vitro Evaluation of 
Relative Inhibitory Potency of Phlorizin and its Conge 
ners”, Am. J. PhysioL, Vol. 209, No. 3, September 
(1965)). Clearly, however, since the af?nity for the 
transport site by phlorizin is approximately 1,000 times 
greater than that shown by glucose, some feature of the 
aglucone moiety of phlorizin facilitates the interaction 
of the glucosidic portion of the molecule with the re 
ceptor. As a result of the interaction, the stability of the 
phlorizin formed complex is much greater than that 
formed with the free sugar. 
Further experiments with phlorizin and other struc 
turally related glycosides have resulted in the identi?ca 
tion of several features which describe the critical struc 
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ture of a potent inhibitor of the absorption of glucose. 
The inhibitory agent is one that possesses atomic group 
ings in a speci?c three-dimensional pattern. The pattern 
favors an association with the membrane receptor. The 
molecule is visualized to be bound at two or more loci. 
A primary bond is formed through the interaction of the 
glycosidic moiety with appropriate groups of the mem 
brane constituent. The linkage presumably is formed 
through hydrogen bonds that involve at least the hy 
droxyl groups on G3 and C-4 of the sugar group. The 
most stable primary interaction occurs when these hy 
droxyl groups are situated in the more chemically reac 
tive equatorial position. A secondary bonding of the 
aglucone portion of the inhibitor molecule to a locus on 
the biological surface is adjacent to, but removed from 
the plane of the glucose transporting site. The linkage is 
probably through hydrogen bonding between the oxy 
gen of the 4-hydroxyphenyl moiety and a membrane 
constituent capable of serving as a hydrogen donor at 
physiological pH. The locus is approximately 13-16 A 
A removed from the transport site to which glucose is 
normally bound. 
The present invention uses the information gained 
from the studies of the geometric con?guration and 
chemical structure of the inhibitory mechanism of 
phlorizin, phloretin and related derivatives and ad 
vances the art by providing compounds and composi 
tions having pharmacological ef?cacies. Particularly 
the compounds act as pharmacological agents that are 
clinically useful and safe in inhibiting sugar uptake with 
out systemic side effects. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present 
invention to provide innovative and novel compounds 
having phloretin or phlorizin moieties and pharmaco 
logical ef?cacies. A method for the manufacture of 
these compounds is also provided. 
A further object of the invention is to provide certain 
phloretin and phlorizin derivative containing com 
pounds that act as specific inhibitors of glucose absorp 
tion from the intestine. 
An additional object of the present invention is to 
provide new phloretin and phlorizin derivative contain= 
ing compounds that are clinically safe and useful to 
selectively inhibit glucose absorption from the intestine. 
A still further object of the invention is to provide 
certain phloretin and phlorizin derivative containing 
compounds and methods for their use in the manage 
ment and treatment of sugar transport disorders. 
Another object of the present invention is to provide 
novel phloretin and phlorizin derivative containing 
compounds and pharmaceutical compositions for inhib 
iting sugar absorption from the intestinal tract. 
A still further object of the invention is to provide 
phloretin and phlorizin derivative containing com 
pounds, pharmaceutical compositions and methods for 
their use in the treatment of diabetes, obesity and dump 
ing syndrome. 
Other objects and advantages of the present invention 
will become apparent as the description thereof pro 
ceeds. 
In satisfaction of the foregoing objects and advan 
tages, there is provided by this invention compounds of 
pharmacological ef?cacy including phloretin and/or 
phlorizin moieties formed from an intermediate deriva 
tive selected from those of the following formulae: 
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R1 
R OH OH 
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II 
OH O 
OH 
OH O§ 
O 
HO O OH 
HO OH 
R1 
wherein R is —OH or —H and R1 is a primary amine 
moiety. Speci?c examples of intermediate compounds 
used to form the complete compound of the invention 
include 4'-deoxyphlorizin-5'-benzylamine, phlorizin-5' 
benzylamine and phloretin-3'-benzylamine. 
In accordance with the objects and advantages of the 
present invention, compounds for inhibiting sugar up 
take from the small intestine comprise a reaction prod 
uct formed from serially coupling (1) an undigestible 
and non-absorbable matrix with a leash forming com 
pound to form a ?rst intermediate product; (2) the ?rst 
intermediate product with an intermediate phloretin or 
phlorizin derivative (as de?ned above) to form a second 
intermediate product; and (3) the second intermediate 
product with a promoter forming compound that en 
hances the affinity of the resulting sugar uptake inhibi 
tory compound of the invention for the surface mem 
brane of the small intestine. 
The matrix is a polysaccharide with monomeric units 
ranging from 150-500. The individual monomers may 
include glucose, mannose, galactose or any mixtures of 
these. The monomers may also carry appropriate func 
tional groups on either the free primary hydroxyl or the 
free secondary hydroxyls. Functional groups include 
carboxymethyl (—O-—CH2—CO2H), 2-hydroxy-3 
bromopropyl (—O--CH2—CHOH-CH2Br), amino 
propyl-diethoxysilane (—-Si(OC;>_H5)2—C3H6NH2), 
amine (—NH;), and amide (—NH--CO—CH3). Prefer 
ably, the matrix is of high molecular weight of from 
25,000 to 90,000 daltons with even higher values possi 
ble. Speci?c examples of matrices include carboxy 
methylcellulose; sodium carboxymethylcellulose; a car 
boxymethyl derivative of a galactomannan from the 
guar plant (available as Jaguar CMG; from Celanese 
Corporation); a dextran, such as BHP-activated Dex 
tran 70 (available from Pharmacia Fine Chemicals, 
Uppsula, Sweden); CH-Sepharose (available from Phar 
macia Fine Chemicals); and a N-hydroxysuccinimide 
activated ester of a derivatized cross-linked agarose gel 
bead support, such as Af?gel 15 (available from Biorad 
Laboratories). 
The leash forming compounds are coupled via amide 
linkages with the functional groups of the matrix. The 
leashes or spacer arms formed serve to hold the later 
coupled inhibitory phloretin or phlorizin derivatives 
away from the backbone of the matrix for reaction with 
the sugar transporter of the intestinal membrane. For 
example, the leash forming compounds couple to 
4,760,135 5 
0—l0O% of the carboxy groups of a sodium carboxy 
methylcellulose matrix. Speci?c leash forming com 
pounds include glycine; N,N-diaminopropylmethyla 
mine; tartaric acid; glutardialdehyde; and amino acids 
with the formula NH2—(CHOH),,—CO2H, wherein 
n: 1-6. ' 
The intermediate phloretin or phlorizin derivative is 
then coupled to the ?rst intermediate product formed 
by coupling the leash forming compound with the ma 
trix. The coupling is through the amine moiety of the 5’ 
C of a phlorizin intermediate compound or the 3’ C of a 
phloretin intermediate compound. The amine moieties 
bind remaining unbound functional groups of the matrix 
and the distal ends of the leash forming compounds via 
amide linkages that are resistant to the proteolytic en 
zymes of the digestive tract. 
The resulting second intermediate product is then 
coupled with a promoter forming compound. Promoter 
forming compounds include ethylenediamine and etha 
nolamine. The promoter forming compound couples to 
any remaining free functional groups of the matrix fol 
lowing coupling of the matrix, leash forming compound 
and intermediate phloretin or phlorizin derivatives. 
In an additional aspect of the present invention, in 
accordance with its objects and purposes, sugar uptake 
inhibiting compositions are provided having as the ac 
tive ingredient compounds as set forth above. Methods 
are also provided for using these compositions in treat 
ing diabetes and dumping syndrome, as well as in pro 
moting weight loss. Each of these methods involves the 
administration to the patient of an effective dosage of 
the sugar uptake inhibitory compounds of the invention. 
The effective dosage is administered in the form of a 
pharmaceutical preparation or composition wherein the 
inhibitory compound is admixed with a pharmaceutical 
organic or inorganic excipient. Suitable excipients are 
substances that do not react with the novel inhibitory 
compounds. Speci?c examples of such excipients in 
clude water, gum and starch. Of course, other known 
medicinal excipients may be used. The compositions 
may be designed to be taken orally in tablet or capsule 
form. Preferably, the compositions are administered in 
an enteric-coated form to protect the amide linkages 
connecting the various ligands with the non-digestible 
matrix from the acidic environment of the stomach. 
In another aspect of the invention, in accordance 
with its objects and purposes, a method for the prepara 
tion of compounds effective in inhibiting sugar uptake 
in the small intestine without harmful side effects is 
provided. The method involves the steps of: (1) cou 
pling a leash forming compound with an undigestible 
and non-absorbable matrix to obtain a ?rst intermediate 
product; (2) coupling the ?rst intermediate product 
with an intermediate phloretin or phlorizin derivative to 
obtain a second intermediate product; and (3) coupling 
the second intermediate product with a promoter form 
ing compound. 
The initial coupling step includes the steps of mixing 
the leash forming compound and matrix together in 
solution and adding a catalyst to promote the coupling 
and the formation of the ?rst intermediate product. 
During the reaction, the pH of the solution is main 
tained at substantially 5.8. The resulting ?rst intermedi 
“A ate product is then puri?ed by dialyzing. 
The second coupling step includes the steps of dis 
solving the ?rst intermediate product, for example, a 
glycine-carboxymethylcellulose matrix, in water and 
the intermediate phloretin or phlorizin derivative in 
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ethanol. The solutions are then mixed together and 
brought to a pH of substantially 5.8 with the ethanol 
level of the mixed solutions being approximately 15%. 
Following the adding of a catalyst to promote the for 
mation of the second intermediate product, the pH and 
ethanol concentration are maintained at these levels. 
The resulting second intermediate product is then puri 
?ed by chromatography. 
The third coupling step includes the steps of forming 
a solution of the second intermediate product and pro 
moter forming compound and adding a catalyst to this 
solution to promote the coupling. The resulting reaction 
product is then puri?ed by chromatography. 
In each coupling step, the added catalyst is l-ethyl-3 
(3-dimethylaminopropyl) carbodiimide (hereinafter 
EDAC). This catalyst promotes coupling through 
amide linkages as explained in Bodansky, M. and On 
dett, M.S., Peptide Synthesis (Interscience, New York, 
1966). 
DETAILED DESCRIPTION OF THE 
INVENTION 
As indicated above, this invention relates to certain 
innovative and novel compounds formed from coupling 
an intermediate phloretin or phlorizin derivative to an 
undigestible and non-absorbable matrix. The resultant 
compounds have pharmacological ef?cacies (1) since 
the phloretin or phlorizin moiety acts as an inhibitor of 
sugar uptake through a mechanism involving the sugar 
transporter of the intestine and (2) the undigestible and 
non-absorbable matrix prevents the phloretin or phlori 
zin from entering the bloodstream and causing systemic, 
toxic effects throughout the body tissues. > 
The phloretin derivatives used as intermediates in 
preparing the inhibitory compounds of the present in 
vention are substituted in the 3’ C position by various 
primary amines. The phlorizin derivatives used as inter 
mediates in preparing the inhibitory compounds of the 
present invention are substituted in the 5' C positon also 
with primary amines. Benzylamine is just one example 
of an appropriate amine that may be used for this substi 
tution resulting in the formation of phloretin-3'-benzyla 
mine, 4'-deoxyphlorizin-5’-benzylamine and phlorizin 
5'-benzylamine. 
Substitution of a primary amine in the positions indi 
cated assures that the critical structure and geometric 
con?guration of the phloretin and phlorizin moiety 
responsible for and essential to sugar transport inhibi 
tory action are retained. Further, the free amino termi 
nus of the primary amine provides the structure neces 
sary for linking the inhibitor derivative to the undigest 
ible and non-absorbable matrix via an amide linkage. 
The amide linkages formed are resistant to the proteo 
lytic enzymes of the digestive tract. For example, exo 
peptidase enzymes require a terminal free amino acid 
and none are present in the resulting compound of the 
invention. Further, the internal amide bonds should not 
be cleaved by endopeptidases since critical recognition 
moities, such as lysine and arginine, are not present. The 
amide bonds are also unaffected by the mildly alkaline 
conditions of the small intestine. Thus, the compounds 
of the present invention pass through the intestine in 
tact, thereby eliminating the toxic and systemic side 
effects associated with unbound phloretin and phlorizin 
as known in the art. 
The compounds of the present invention are formed 
by serially coupling an undigestible and non-absorbable 
matrix with a leash forming compound, an active inter 
4,760,135 
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mediate phloretin or phlorizin derivative and a pro 
moter forming compound. The matrix is a polysaccha 
ride having 150-500 monomeric units of glucose, man 
nose, and/or galactose. Appropriate functional groups 
are provided on the free primary hydroxyl or free sec 
ondary hydroxyls of the monomers as coupling sites. 
Functional groups include carboxymethyl, 2-hydroxy 
3-bromopropyl, aminopropyl-diethoxysilane, amine and 
amide. The matrix is of a high molecular weight of at 
least 25,000—90,000 daltons. 
Carboxymethylcellulose (CMC) is just one example 
of an undigestible and non-absorbable matrix bearing 
staple spacer arms of appropriate length so that each 
attached inhibiting phloretin or phlorizin moiety is held 
away from the polymeric backbone and free to interact 
with and inhibit the glucose transporter in the intestinal 
cell membrane. Sodium substituted carboxymethylcel 
lulose (cellulose gum; available from Hercules, Inc.) is 
inexpensive and has stable —O—CH1CO2H groupings 
that can easily be extended by glycine through which 
the inhibitor moiety may be attached. It also possesses a 
carbohydrate skeleton that is resistant to mammalian 
amylases. Further, the sodium provides improved water 
solubility over the unsubstituted carboxymethylcellu 
lose. This improved solubility aids in the method of 
producing the compounds of the present invention as 
will be discussed below. 
A carboxymethyl derivative of a galactomannan 
from the guar plant may also be used. It is a water-misci 
ble gel having a molecular weight of about 220,000 
daltons. It also is not digestible by the mammalian intes 
tine. 
A small, water soluble cross-linked dextran having a 
molecular weight of about 70,000 daltons may be used 
as a matrix material. The dextran matrix has the advan— 
tage of accessibility to the intestinal mucosa. Further, it 
is available from Pharmacia Fine Chemicals in a 
bromohydroxypropyl activated form. The bromohy 
droxypropyl groups react with primary amines, such as 
the benzylamine moiety of the intermediate inhibitor 
derivative to form stable secondary amine linkages, 
thereby avoiding the formation of peptide linkages that 
may be cleaved by peptidases in the gut. 
CH-Sepharose could also be used as a matrix mate 
rial. Advantageously, it offers a stable, hydrophobic 
leash for spacing the inhibitor derivative from the ma 
trix backbone so that it is more suitably located for 
reaction with the sugar transporter of the brush border 
membrane. While one peptide bond is required in the 
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linkage, it is formed with the aromatic amino group of 50 
an inhibitor derivative such as phlorezin-5’-benzylamine 
and, therefore, is highly unlikely to be cleaved by pepti 
dases. 
A further example of a matrix material is a N-hydrox 
ysuccinimide-activated ester of a derivatized cross 
linked agarose gel bead support (such as Af?gel 15 
available from Biorad Laboratories). Although it is 
insoluble, it can be used to couple an amine containing 
ligand, such as phlorezin-S'-benzylamine, spontaneously 
in aqueous solution. The matrix includes a l5-atom 
spacer arm containing a cationic charge that advanta 
geously signi?cantly enhances its interaction with the 
negatively charged outer sialoglyco-proteins of the 
mucosa. This serves to direct the inhibitor moiety 
toward its site of action. 
A leash forming compound is coupled to the matrix 
material to form a ?rst intermediate product. The molar 
proportions of the leash forming compound to the ma 
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trix compound should provide for 0-100% coupling of 
the leash forming compound to the functional groups of 
the matrix The leash forming compound serves to 
project from the backbone of the matrix and provide a 
site for attachment of the inhibitor moiety allowing free 
interaction between the inhibitor moiety and the trans 
porter in the membrane. Glycine is the preferred leash 
forming compound. It provides a stable “spacer arm” 
for attachment of the inhibitor moiety to the matrix. 
The amide bonds formed between the glycine and the 
inhibitor derivative resist cleavage by the proteolytic 
enzymes of the digestive tract to retain the compound 
of the present invention intact. Glycine also adds “?exi 
bility” to the inhibitor moiety. Glycine forms a variety 
of leash links due to the presence of dimers and trimers 
of glycine. Thus, some of the inhibitor moieties should 
always be a favorable distance from the brush border 
membrane to readily react with the transporter of the 
membrane surface. Examples of other leash forming 
compounds include N,N-diaminoproplymethylamine, 
tartaric acid, glutardialdehyde, and amino acids with 
the formula NH2—(CHOH)n—-CO2H, wherein n: 1-6. 
The ?rst intermediate product resulting from the 
coupling of the matrix to the leash forming compound is 
then coupled with the intermediate phloretin or phlori 
zin primary amine derivative to form a second interme 
diate product. The coupling of the inhibitor moiety to 
the ?rst intermediate product is through the amine 
group so as to provide an amide linkage. Coupling of 
the inhibitor moiety occurs at the ends of the leash 
forming compounds on the matrix or to the functional 
groups of the matrix previously uncoupled by the leash 
forming compound. Thus, inhibitor moieties of the 
compound of the present invention are located at vary 
ing distances from the matrix backbone so that some of 
the inhibitor moieties are always located in the ideal 
position for interacting with the transporter of the brush 
border membrane. 
The compound resulting from serially coupling the 
leash forming compound and intermediate inhibitory 
compound to the matrix may itself be used for inhibiting 
sugar uptake in the treatment of diabetes, obesity and 
dumping syndrome. It should be recognized, however, 
that there may still remain free functional groups on the 
matrix such as carboxy groups that tend to make the 
resulting compound highly anionic at neutral pH’s. 
Since the brush border membrane is highly negatively 
charged, repulsive forces may be present to prevent this 
compound from effectively interacting with the mem 
brane. In order to overcome this problem, it is preferred 
to use the compound resulting from serially coupling 
the leash and inhibitor moieties to the matrix as a second 
intermediate product. The second intermediate product 
is then coupled to a promoter forming compound." The 
promoter forming compound couples to and covers up 
any remaining free carboxy groups or other functional 
groups on the matrix previously unreacted with the 
leash forming compound or the intermediate inhibitor 
derivative. Advantageously, the promoter forming 
compounds not only reduce or eliminate the polyan 
ionic nature of the second intermediate product, but 
they also enhance the af?nity of the resulting inhibitor 
compound of the present invention for the membrane 
surface by contributing positive charges to the com 
pound through their free amino termini. Speci?c exam 
ples of promoter forming compounds include ethylene 
diamine and ethanolamine. Like the leash forming com 
pounds and the intermediate inhibitor compounds cou 
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pled to the matrix, these promoter forming compounds 
are linked via amide linkages that are resistant to cleav 
age in the digestive tract. 
In accordance with another aspect of the present 
invention, the compounds may be utilized in a method 
of treating diabetes. Particularly, the compounds of the 
present invention inhibit sugar uptake and provide con 
trol of post-prandial hyperglycemic episodes. Advanta 
geously, the compounds of the present invention do this 
without toxic side effects and without inhibiting uptake 
of other essential nutrients. 
The compounds may also safely be utilized in a 
method to provide weight control. By selectively inhib 
iting sugar uptake the compounds provide a reduction 
in absorbed calories without the need of harsh dietary 
discipline. By this, it is meant that a normal meal may be 
ingested but it provides fewer absorbed calories just as 
if food intake were reduced. 
Additionally, the compounds may be utilized in a 
method of treating dumping syndrome. Following a 
gastrointestinal resection, food passes directly into the 
small intestine. This results in a very rapid increase of 
sugar absorption into the bloodstream. The pancreas 
then reacts by producing more insulin. The reaction 
time is too slow, however, and the peak insulin level 
occurs well after peak sugar levels. Thus, the blood 
glucose drops rapidly rather than leveling off as would 
normally occur. This results in hypoglycemia and, in 
severe cases, loss of consciousness. The compounds of 
the present invention avoid this problem by initially 
inhibiting absorption of the sugar. Thus, the compounds 
reduce or eliminate the very rapid increase of sugar 
absorption, thereby reducing the high insulin require 
ments of the individual and the degree of reaction of the 
pancreas. Consequently, the compounds of the present 
invention prevent the large ?uctuation in blood glucose 
levels typical of dumping syndrome and that often re 
sult in loss of consciousness. 
Preferably, compounds of the present invention are 
administered orally in tablet or capsule form. The tab 
lets or capsules may include an enteric coating to pro 
tect the compound from the acidic environment of the 
stomach. The tablets and capsules may include a com 
position having compounds of the present invention, as 
the active ingredient, admixed with excipients known in 
the art. Thus, the tablet or capsule may contain a gum, 
starch, gelatin or even a buffer. The dosage for treat 
ment with the inhibitory compounds of the present 
invention depends on such factors as the age, weight 
and condition of the individual patient as well as the 
condition being treated. The compound should be ad 
ministered before meals if maximum effect is to be ob 
tained. 
In accordance with still another aspect of the inven 
tion methods for making the inhibitory compounds are 
provided. The methods include coupling a primary 
amine derivative of phloretin or phlorizin in accordance 
with one of the following formulae: 
R1 
OH OH 
and 
OH 
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-continued 
OH 
OH 0§ @ 
0 
Ho 0 on 
HO OH 
R1 
R 
wherein R is --OH or H and R1 is a primary amine 
moiety; to an undigestible and non-absorbable matrix. 
The method includes the initial step of coupling a 
leash forming compound with the matrix to form a ?rst 
intermediate product. The leash forming compound and 
matrix are preferably dissolved in water but other ap- 
propriate solvents may be used. The pH of the solutions 
containing the compounds is then brought to about 5.8 
as, for example, by the addition of HCl as necessary. 
EDAC catalyst is then added to the solution to promote 
the coupling through amide linkages. During the cou 
pling the solution pH is maintained at substantially 5.8. 
Following completion of the reaction, the solution con 
taining the ?rst intermediate product is puri?ed. The 
purifying step is performed by dialyzing the solution 
against water to remove the remaining catalyst, excess 
starting materials and any unwanted by-products of the 
reaction. 
The puri?ed ?rst intermediate product is then again 
dissolved in water and the intermediate inhibitory 
phloretin or phlorizin compound is dissolved in an ap 
propriate solvent miscible with water, such as ethanol. 
The solutions containing the ?rst intermediate product 
and intermediate inhibitory compound are then mixed 
together with the pH level brought to substantially 5.8 
and the ethanol level brought to approximately 15%. 
EDAC catalyst is added to the mixed solutions to pro 
mote the formation of amide linkages between the inter 
mediate inhibitory compound and the ends of the 
leashes and/or any unreacted functional groups of the 
matrix. The EDAC catalyst promoted amide linkages 
between the inhibitory compound and the matrix are 
not cleaved by the enzymes of the gastrointestinal tract 
and the phloretin/phlorizin moiety remains bound to 
the matrix. Thus, the phloretin/phlorizin moiety does 
not enter the bloodstream and elicit toxic effects on 
other organs of the body. 
Following chromatographic puri?cation, the result 
ing second intermediate product may be utilized in a 
method of treating individuals where inhibiting sugar 
uptake is desired. It is preferred, however, to couple the 
second intermediate product to a promoter forming 
compound so as to increase the af?nity of the inhibitor 
product of the present invention for the mammalian 
brush border membrane. This is done by preparing a 
solution of the second intermediate product and the 
promoter forming compound. The pH of this solution is 
brought to substantially 5.8 and EDAC catalyst is 
added to promote the coupling. 
The following examples are presented to illustrate the 
invention but it is not to be considered as limited 
thereto. 
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EXAMPLE 1 
Phlorizin (7 mmol) and p-nitrobenzaldehyde (5 
mmol) were dissolved in 84 ml methanol and cooled to 
0° C. Under a nitrogen atmosphere, 14 meq of l N KOH 
were added dropwise with magnetic stirring and the 
reaction was allowed to incubate for 2 hr at 0° C. and 
then 1.5 hr at 50° C. The reaction mixture was recooled 
to 0° C. and neutralized by the dropwise addition of 14 
meq of 0.5 N HCl. The solvent was removed in vacuo 
to yield a brown syrup containing primarily the pre 
sumed carbinol (carbinol was not suf?ciently stable to 
be analyzed) and unreacted phlorizin. The mixture was 
dissolved in 10 ml CHC13/CH3OH (4:1) and subjected 
to flash chromatography on a column of Silica Gel 60 
(4.5 X26 cm) that had been pressure packed with chlo 
roform. Elution was conducted with 0.75 L 15% metha 
nol in chloroform, followed by 0.5 L 18% and then 0.5 
L 22% of the same solvent mixture. Thin layer chroma 
tography was used to monitor the fractionation: the 
eluate volume between 0.4-0.5 L contained essentially 
pure 2'-O-B-D-glucopyranosyl)-5'-p-nitrobenzyl carbi 
nol (herinafter called GNC) (0.8 g, 20%) while the 
0.5-1.4 L eluate contained 2.4 g of a mixture of GNC 
contaminated with approximately 20% phlorizin. Rf 
value of the presumed carbinol GNC in 25% 
Me0H/CHCl3 was 0.25. 
Compound GNC (0.96 g in 100 ml methanol) was 
catalytically hydrogenated with 150 mg 10% Pd on 
charcoal for 1 hr at 22° C. at atmospheric pressure, and 
then 3 hr at 55° C. at 30 cm H2O pressure. At lower 
temperatures reduction was incomplete and yielded an 
unstable orange product. The catalyst was removed and 
the methanol was evaporated in vacuo to yield crude 
phlorizin-5'-benzylamine (0.84 g, 92%) The product 
was dissolved in 8 ml methanol and mixed with 10 ml 
Sephadex G-l0 slurry equilibrated in 50% methanol. 
Finally 8 ml H2O was added and the resulting slurry 
was added to the top of a Sephadex G-10 column 
(2.5 X27 cm) likewise equilibrated in 50% methanol. 
Elution was conducted with 0.8 L 50% methanol fol~ 
lowed by 0.7 L 55% methanol and 1.0 L 60% methanol. 
The amine was eluted in the 1.1-2.0 L fraction. If the 
amine had been contaminated prior to this chromatog-: 
raphy, phlorizin was readily separated at this step and 
could be recovered in the 0.36-0.66 L fraction. Phlori 
zin-5’-benzylamine was obtained by evaporating the 
solvent and crystallization from aqueous methanol as 
the monohydrate (0.55 g, 60%); after drying at 80° C. in 
vacuo its m.p. was 197°-200° C. 
Elemental Analysis: C H N 
Calculated for CZ8H3[O1QN.H2OZ 60.10 5.94 2.54 
Found for the reaction product: 60.30 5.90 2.51 
In order to verify that the reaction conditions were 
suf?cient to reduce the secondary hydroxyl group of 
GNC, the phlorizin-5'~benzylamine reaction product 
was quantitatively acetylated with acetic anhydride in 
the presence of pyridine. Theoretical incorporation is 8 
moles acetate/mole glycoside. Found for phlorizin-5’ 
benzylamine: 7.82 moles acetate/ mole phlorizin-5'-ben 
zylamine (97.8%). 
An acetamide derivative of the reaction product pre 
pared by coupling acetic acid and the amine in methanol 
with EDAC, was crystallized from 30% methanol as 
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the monohydrate. After drying at 80° C. in vacuo its 
m.p. was: 215° C. after softening at 149° C. 
Elemental Analysis: C H N 
Calculated for C30H33O11N: 61.64 5.69 2.49 
Found for acetamide derivative 61.58 5.90 2.32 
of the reaction product: 
The structure proposed for compound phlorizin-5’ 
benzylamine was con?rmed by comparing its proton 
NMR spectra with that of phlorizin. The AZBZ pattern 
at 2.88 and 3.50 ppm arising from the —CH2CH2. 
CO-moiety in phlorizin also appears at 2.87 and 3.49 
ppm in the spectra of phlorizin-5'-benzylamine (in both 
compounds the triplet at 3.5 ppm is partially obscured 
by the signals arising from the protons in the glucose 
moiety). The B-ring AA'BB’-system at 6.72 and 7.10 
ppm remained unchanged, but phlorizin’s A-ring AB 
system at 5.99 and 6.25 ppm was converted to a l H 
singlet at 7.42 ppm in compound phlorizin-5’-benzyla 
mine. The new C ring AA'BB' system in compound 
phlorizin-S'benzylamine gave signals at 6.54 and 6.98 
ppm and the new -—CH2 group is seen as a 2H singlet at 
3.72 ppm. The reaction is schematically shown below. 
no 0T 
0 
H0 H0 0 OH 
OH 
KOH/MeOH 
PHLORIZIN pNOz/CéHSCHO 
on 
0% 
O OH 
GLC/ I 
t" @ on on
GNC Hz/Pd/C 
55" c. 
HN02/NaN3\L HOAC/EDAC 
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OH 
PHLORIZlN-5’- o% 
0 01-1 GLC/ 
CH R 
on 
BENZYLAMINE 
(X) R = _NH3 
no 
0 
GLC = HO HO 
OH 
This example demonstrates the synthesis of an inter 
mediate phlorizin derivative having a primary amine 
moiety on the 5’C. The synthesis of an intermediate 
phloretin derivative having an primary amine moiety on 
the 3’C is set forth in “Phloretinyl-3'-benzylazide: A 
High Af?nity, Probe for the Sugar Transporter in 
Human Erythrocytes”, Fannin, F. F., Evans, J. 0., 
Gibbs, E. M., Deidrich, D. F., Biochemica et Bio 
physica Acta, 649 (1981) 189-201. 
EXAMPLE 2 
Sodium carboxymethylcellulose (CMC) (0.0625 gm; 
0.213 mmoles of —COZH groups i.e. 70% of anhydro 
glucose units carry carboxymethyl groups) was dis 
solved in 9 ml of water. To this solution was added 1 ml 
aqueous solution of 80 mg radioactive glycine (1.066 
mmoles; l.2p.Cil4C). The solution was made to a pH of 
5.8 with 0.2 N HCl. Then 123 mg of solid EDAC was 
added with stirring. As successful coupling reactions 
consumed hydrogen ions, the pH was maintained at 5.8 
by the addition of 0.2 N HCl as required. 
The resultant reaction mixture was then dialyzed 
against 1 liter of water for 7 hours using a Spectrapor 
dialysis membrane (MW cutoff 6,000~8,000 daltons). 
This was done as it is important to remove excess start 
ing materials, by-products and spent catalyst from the 
?rst reaction in order to perform the next coupling step 
in the overall synthesis set forth in Example 3 below. 
A number of other test reactions were performed to 
ascertain the optimal reaction conditions that yield the 
greatest coupling of CMC and glycine. 
TABLE 1 
EXTENT OF REACTION: 
mMoles of Glycine coupled 
to CMC carboxyl groups 
total mMoles of available, 
reactive carboxyl groups 
MOLAR RATIOS OF 
@@E 
Rxn I-pH 5.8 82% 
1:5:3 
Rxn Il-pH 5.8 87% 
1:10:15 * 
Rxn Ill-pH 6.8 35% 
15:3 
Rxn lV-pl-I 6.8 55% 
121023 
Rxn V-pl-l 4.8 0% 
1:10002100 
RXl'l VI-pl-l 6 0% 
1210002100 
The pH of the reaction as well as the molar ratios of the 
materials (CMC-matrix carboxyl groups: glycine li 
gand; EDAC catalyst) were varied. The % yield of 
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glycinated cellulose was assessed by Sephadex gel ?ltra 
tion. Speci?cally, the radioactive glycinated-cellulose 
product (?rst intermediate product of the overall syn 
thesis) was separated from excess starting materials, 
by-products and catalyst using a Sephadex G-25 col 
umn. Void volumes (determined with Blue Dextran) 
and approximate column volumes were 11 ml and 22 ml, 
respectively. Aliquots of reactions I-VI from Table l 
were applied and eluted with water. Then one ml frac 
tions were collected and assayed for I4C. 
As shown in FIG. 1, the small Sephadex column 
readily separated the 90,000 dalton glycinated-cellulose 
product from the low molecular weight unreacted gly 
cine and other products (dimers and trimers, etc. of 
glycine) that enter the beads and were eluted only after 
a column volume of water. The results of these tests, 
summarized in Table 1, indicate that: 
(1) high molar ratios of glycine and EDAC catalyst 
relative to the equivalents of available CMC-carboxyl 
groups prevent coupling (see reactions V and VI); ap 
parently the excess glycine -—CO2H’s compete with 
those on the CMC such that only glycylglycine and 
higher oligomers are formed; and 
(2) the lower pH of 5.8 improves yield and when 
molar ratios of CMC-—CO2H: glycine: catalyst are 
l:l0:3, over 80% coupling occurs. 
EXAMPLE 3 
To the dialyzed ?rst intermediate product of Exam 
ple 2 was added 190 mg of radioactive phlorizin-S-ben 
zylamine (0.35 mmoles; l00p.Ci3H) in ethanol from 
Example 1. Solid EDAC catalyst (100 mg; 0.52 mmoles) 
was then added to the solution and the reaction was 
allowed to proceed for six hours. During this time the 
ethanol level of the solution was maintained at 15%, the 
temperature of the solution at 35°-40° C. and the pH 
was maintained at 5.8. The reaction yielded a white 
product (CMC-glycine-phlorizin-S'-benzylamine) as a 
suspension with 20% of the -CO2H groups coupled 
with the amine derivative of phlorizin. 
To 6.5 ml of the suspension was added l50p.L of 0.5 
N NaOH to dissolve the product. This solution was 
then chromatographed on a Sephadex G-25 column 
(void volume 180-190 ml; hold up volume, 275 ml) with 
water as eluant. The second intermediate product, 
CMC-glycine-phlorizin-S'-benzylamine, was eluted in 
25 ml at about the void volume. The second intermedi 
ate product was completely separated from unreacted 
3H-phlorizon-5'-benzylamine because that starting ma 
terial is tightly absorbed to the Sephadex G-25 and 
requires ethanol to be eluted. 
Aliquots of the fractionated reaction product were 
used to determine the extent of binding between the 
CMC—-[14C] glycine and the [3H] phlorizin-5'-benzyla 
mine. The amount of CMC-reactive groups recovered 
in the water elution (92%, as determined from the [14C] 
CPM applied) was compared to the phlorizin-5’-ben 
zylamine present in these same fractions (as measured 
by the bound [3H] CPM). 
Aliquots of the Sephadex G-25 puri?ed second inter 
mediate product were also examined with a TNBS 
assay (see Antoni, G., Presentini, R. and Neri, P., Anal. 
Biochem. 129 (1983) 6063). The reagent 2,4,6-trinitro 
benzene sulfonic acid forms a yellow color with free 
primary amine groups that is measured spectrophoto 
metrically. The results of the analysis indicate that the 
G-25 puri?ed product contained only trace amounts of 
4,760,135 
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free amino groups. Therefore, from 87-100% of the 
phlorizin-5'-benzylamine is coupled to the matrix 
through the amino group. Had the ligand been coupled 
in reverse fashion as, for example, through its phenol 
groups, free amino groups could have been detected. 
An awareness of the mode of coupling is crucial since 
phlorizin possesses sugar transport inhibitory properties 
only when the phenolic groups are free to react with the 
cell membrane surface. Thus, the phlorizin moieties 
bound to the cellulose matrix in this preparation are in 
optimal con?guration for interaction with the intestinal 
sugar transport system. 
Further experimentation has shown that the pre 
ferred molar ratio of glycinated CMC to phlorizin-5’ 
benzylamine to EDAC catalyst is 1:0.2:0.75. While 
larger amounts of phlorizin-5’-benzylamine may be 
readily incorporated into the product, such incorpora 
tion results in a loss of water solubility. The loss of 
water solubility is to be avoided as it adversely effects 
the ef?ciency of the following reaction step and the 
pharmacological activity of the completed compound. 
EXAMPLE 4 
To a 9 ml aliquot of the eluted solution of Example 3 
containing the second intermediate product (CMC-gly 
cine-phlorizin-S'-benzylamine) (containing approxi 
mately 2 mmoles of underivatized —CO2H groups) was 
added 125 uL of a solution containing 10.6 mmoles of 
ethanolamine hydrochloride. The pH of the solution 
was brought to 5.8 and 2 mg. of solid EDAC catalyst 
was added. The addition of the catalyst resulted in a 
rapid increase in pH signifying the coupling of the 
amine to the matrix. Within 1 hour the pH decreased to 
about 5 signifying near completion of the reaction. The 
mixture was then maintained at 4 C overnight. The ?nal 
product was puri?ed by chromatography on a Sepha 
dex G-25 column. Eighty-eight percent of the radiola 
beled product was recovered and it possessed the ex 
pected l‘lC/3H ratio of 0.018. 
EXAMPLE 5 
An animal study was then conducted to determine 
whether bacterial and other digestive action would split 
the inhibitory compound of the present invention, 
thereby leading to the absorption of toxic fragments. 
The radioactive labeled compound of Example 4 (0.3 
/].L Ci 3H labeled phlorizin moiety; 0.04;.tCi14C labeled 
CMC) was inserted into the bowels of a single rat that 
possessed a cecal ?stula. No radioactivity was found in 
the blood plasma one or six hours after administration. 
Furthermore, the radioactive material recovered from 
the bowel contents contained a 3H/14C ratio equal to 
that of the original material. Thus, fragmentation and 
selective absorption or disposal of either labeled frag 
ment did not occur. 
In summary, numerous bene?ts have been described 
which result from employing the concepts of the pres 
ent invention. A novel intermediate compound having 
potential pharmacological ef?cacies is disclosed. Com 
pounds having selective sugar transport inhibitory ac 
tion are also disclosed. These compounds include an 
amino derivative of phloretin or phlorizin bound 
through an amide linkage to an undigestible and non 
absorbable matrix. Thus, the compounds avoid the 
known systemic effects of phlorizin and phloretin while 
advantageously providing their speci?c inhibitory ac 
tion. Further methods for utilizing the chemically safe 
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compounds in treating diabetics, the obese and gastroin 
testinal resection patients are disclosed. 
The invention has been described herein with refer 
ence to certain preferred embodiments. However, as 
obvious variations thereon will become apparent to 
those skilled in the art, the invention is not to be consid 
ered as limited thereto. 
We claim: 
1. A compound, consisting of: a reaction product 
formed by serially coupling (1) an undigestible and 
non-absorbable polysaccharide matrix with a leash 
forming compound selected from a group consisting of 
glycine, N-N-diaminopropylmethylarnine, tartaric acid, 
glutardialdehyde and NH2—(CHOH),,—COZH 
wherein n: l-6 by dissolving the leash forming com 
pound and matrix together in a solvent maintained at a 
pH of substantially 5.8 and then adding l-ethyl-3-(3 
dimethylaminopropyl) carbodiimide HCl as a catalyst 
to promote coupling and obtain a ?rst intermediate 
product; (2) said ?rst intermediate product with an 
intermediate inhibitory compound selected from a 
group consisting of compounds having the following 
structures: 
R! 
R OH OH 
and 
II 
OH O 
OH 
OH O% 
O 
HO 0 OH 
HO OH 
R1 
wherein R=-—OH or —H and R1 is a primary amine of 
from l-lO carbon atoms effective in inhibiting glucose 
uptake by dissolving said ?rst intermediate product and 
said intermediate inhibitory compound in solvents, mix 
ing the solvents, and adding l~ethyl-3-(3-dime 
thylaminopropyl) carbodiimide HCl as a catalyst to 
promote coupling while maintaining the pH of the 
mixed solvents at substantially 5.8 so as to form a second 
intermediate product; and (3) said second intermediate 
product with a promoter forming compound selected 
from a group consisting of ethylenediamine and etha 
nolamine by dissolving said promoter forming com 
pound and said second intermediate product in solvent 
maintained at a pH of substantially 5.8 and adding 1 
ethyl-3=(3-dimethylaminopropyl) carbodiimide HCl as a 
catalyst. 
2. The compound of claim 1, wherein R1 includes an 
aromatic ring. 
3. The compound of claim 1, wherein said intermedi 
ate inhibitory compound is phlorizin-5’-benzylamine. 
4. The compound of claim 1, wherein said intermedi 
ate inhibitory compound is 4'-deoxyphlorizin-5’-ben 
zylamine. 
5. The compound of claim 1, wherein said intermedi 
ate inhibitory compound is phloretin-3'-benzylamine. 
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6. The compound of claim 1, wherein said polysac 
charide matrix has a molecular weight of from 
25,000—90,000 daltons. 
7. The compound of claim 1, wherein said polysac 
charide matrix includes substantially 150-500 mono 
meric units selected from a group consisting of 
CH0 CH0 CH0 
R R R 
R R R 
and and 
R R R 
R R R 
CHZR CHZR CHZR 
and any mixtures thereof, wherein R=—OH, 
8. The compound of claim 1, wherein said matrix is 
carboxymethylcellulose. 
9. The compound of claim 1, wherein said matrix is 
sodium carboxymethylcellulose. 
10. The compound of claim 1, wherein said matrix is 
a carboxymethyl derivative of a galactomannan from 
the guar plant. 
11. The compound of claim 1, wherein said matrix is 
a water soluble cross-linked dextran of substantially 
70,000 daltons. 
12. The compound of claim 1, wherein said matrix is 
CH-Sepharose. 
13. The compound of claim 1, wherein said matrix is 
an N-hydroxysuccinimide-activated ester of a deriva 
tized cross-linked agarose gel bead support. 
14. A compound effective in inhibiting glucose up 
take in a mammalian intestine, consisting of: a reaction 
product formed by serially coupling (1) a polysaccha 
ride matrix with a leash forming compound selected 
from a group consisting of glycine, N-N-diamino 
propylmethylamine, tartaric acid, glutardialdehyde and 
NH2—(CHOH),,——CO2H wherein n: l-6 by dissolving 
the leash forming compound and matrix together in a 
solvent maintained at a pH of substantially 5.8 and then 
adding l-ethyl-3-(3-dirnethylaminopropyl) carbodiim 
ide HCl as a catalyst to promote coupling and obtain a 
first intermediate product and (2) said ?rst intermediate 
product with an intermediate inhibitory compound 
LII 
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selected from a group consisting of compounds having 
the following structures: 
R1 
R OH OH 
and 
H 
OH O 
OH 
OH O§ 
O 
HO O OH 
HO on 
R1 
R 
wherein R=—OH or -—H and R1 is a primary amine of 
from l-lO carbon atoms by dissolving said ?rst interme 
diate product and said intermediate inhibitory com 
pound in solvents, mixing the solvents, and adding 1 
ethyl-3-(3-dimethylaminopropyl) carboddimide HCl as 
a catalyst to promote coupling while maintaining the 
pH of the mixed solvents at substantially 5,8. 
15. The compound of claim 14, wherein said polysac 
charide matrix includes monomeric units selected from 
a group consisting of 
CH0 CH0 CH0 
R R 
R R R 
and and 
R R R 
R R R 
CHZR CHgR CHZR 
* 1k * * * 
